This review evaluated the effectiveness of 5-hydroxytryptamine (serotonin) antagonists in treating irritable bowel syndrome (IBS). The authors concluded that 5-hydroxytryptamine antagonists significantly improved symptoms of nonconstipated IBS and diarrhoea predominant IBS in men and women, but there was an increased risk of constipation. The authors' conclusions reflect the evidence presented and are likely to be reliable.
Study selection
Eligible for inclusion in the review were randomised controlled trials (RCTs) evaluating the effects of 5-hydroxytryptamine antagonists on the relief of abdominal pain and discomfort, or global improvement, in irritable bowel syndrome (IBS). Review or animal studies, studies with pharmacodynamic endpoints, duplicate publications and non-IBS studies were excluded. Outcomes of interest were relief of abdominal pain and discomfort, global improvement of IBS symptoms, and constipation rate.
In included trials, 5-hydroxytryptamine antagonists were alosetron and cilansetron. Controls were placebo or mebeverine. Gender breakdown varied between included trials. The mean age of patients was approximately the same for both genders (43 to 49 years). Some included trials had patients with diarrhoea-predominant IBS and patients with non-constipated IBS, whilst other trials had patients with diarrhoea-predominant IBS only. Two reviewers independently selected the studies for inclusion in the review. It was not reported how disagreements were resolved.
Assessment of study quality
Trial quality was assessed using the criteria of: a control group; random allocation; blinding of patients and investigators; parallel group design; validated disease definition (Rome 1 and II criteria); validated outcome measures; attrition bias; loss to follow-up; adequate power; definition of responder included a priori; and use of intention-to-treat analysis.
Two reviewers independently assessed study quality. It was not reported how disagreements were resolved.
Data extraction
Data was extracted in order to calculate risk ratios (RR) with 95% confidence intervals (CI).
